

Purification and Molecular Cloning of Calobin, a Thrombin-Like Enzyme from *Agkistrodon caliginosus* (Korean Viper)¹

Bum-Soo Hahn,* Kyoung-Youl Yang,*[†] Eun-Mi Park,[†] Il-Moo Chang,* and Yeong-Shik Kim*²

*Natural Products Research Institute, Seoul National University, Seoul 110-460, Korea; and [†]Department of Chemistry, University of Incheon, Incheon 402-749, Korea

Received for publication, October 24, 1995

A thrombin-like enzyme, calobin, has been purified to homogeneity from the venom of *Agkistrodon caliginosus* by a procedure involving Bio-Gel P-100, Mono S, and Pro-RPC. The enzyme was identified as a monomer with a molecular weight of 34,000 on SDS-PAGE, and its isoelectric point was 6.2. Calobin acted on fibrinogen to form fibrin with a specific activity of 226 NIH equivalent units, and also exhibited arginine esterase activity. The enzyme predominantly cleaved the α -chain of fibrinogen with little degradation of the β -chain. It contained abundant asparagine/aspartic acid residues, but very few tyrosine or methionine residues. The proteolytic activity of the enzyme with TAME as a substrate was higher than that of thrombin. However, it showed neither lysine esterase nor caseinolytic activity. The enzyme activity was strongly inhibited by PMSF, and moderately by benzamidine and soybean trypsin inhibitor, indicating it is a serine protease. On the other hand, the enzyme activity was not inhibited by hirudin or aprotinin. cDNA (1.6 kb) for calobin has been cloned from an *A. caliginosus* cDNA library. The cDNA sequence indicates that calobin is synthesized as a pre-zymogen of 262 amino acids, including a putative secretory signal peptide of 18 amino acids and a proposed zymogen peptide of 6 amino acid residues. The cDNA sequence encodes a 238-amino acid residue molecule exhibiting strong amino acid sequence homology to those of ancrod, batroxobin, and flavoxobin isolated from other snake venoms. Calobin contains 12 cysteine residues. As judged on alignment of the amino acid sequences of other thrombin-like enzymes (batroxobin, ancrod, and flavoxobin), calobin constitute the formation of six disulfide bridges. Amino acid residues, His⁴³, Asp⁸⁸, and Ser¹⁸², which are thought to be the catalytic active site are highly conserved. As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83.

Key words: *Agkistrodon caliginosus*, cDNA sequence, purification, thrombin-like enzyme.

Snake venom is known to contain proteases involved in blood coagulation and fibrinolysis. They are usually divided into serine proteases and metalloproteases, depending on their properties (1-3). Among the serine proteases of snake venoms, thrombin-like enzymes are widely distributed among the venoms of the *Viperidae* and *Crotalidae* families. They have been studied widely because of their therapeutic potential in myocardial infarction and thrombotic diseases (4, 5). The thrombin-like enzymes act enzymatically on a fibrinogen molecule to form a product that cannot be stabilized by factor XIII. Consequently, the thus formed clots are not cross-linked and are susceptible to

degradation by plasmin. As they lower serum fibrinogen, they appear to be an appropriate alternative to heparin and may be preferable to it in hemorrhagic complications.

Recently, we studied two kinds of metalloproteases from the eastern cottonmouth moccasin (*Agkistrodon piscivorus piscivorus*), and found that the two enzymes exhibited different extents of proteolytic activity toward the α - and β -chains of the fibrinogen molecule (6).

Suzuki and Takahashi (7) reported the purification of two kinds of thrombin-like proteins from the venom of the Korean viper (*A. caliginosus*). However, neither their amino acid sequences nor their biochemical characteristics were described. In this study, a low molecular weight thrombin-like enzyme has been purified from the Korean viper and its cDNA cloned from a venom-gland cDNA library. Its nucleotide sequence was determined and the total amino acid sequence was deduced based on the nucleotide sequence.

¹This work was supported by a Grant-in-Aid from the Ministry of Education, Republic of Korea. The nucleotide sequence data reported in this paper have been submitted to the GenBank™ Data Bank under the accession number, U32937.

²To whom correspondence should be addressed. Tel: +82-2-740-8929, Fax: 82-2-742-9951

Abbreviations: BAA, *N* α -benzoyl-L-argininamide; BAEE, *N* α -benzoyl-L-arginine ethyl ester; NA, *p*-nitroanilide; PMSF, phenylmethylsulfonyl fluoride; TAME, *N* α -*p*-tosyl-L-arginine methyl ester; TLEE, *N* α -*p*-tosyl-L-lysine ethyl ester.

MATERIALS AND METHODS

Venom was pooled from the glands of *A. caliginosus* at the

Snake Institute of Seoul, and immediately lyophilized. Mono S™ HR 5/5 and Pro-RPC™ HR 5/5 were purchased from Pharmacia Fine Chemicals (Uppsala, Sweden). Human thrombin, bovine fibrinogen, chromogenic substrates, aprotinin, hirudin, and other reagents were from Sigma Chemicals (St. Louis, USA). All restriction endonucleases, DNA ligase, T4 polynucleotide kinase, and M13mp18/19 were purchased from New England Biolabs (Beverly, USA).

Purification—Calobin was purified sequentially by gel filtration, ion-exchange chromatography, and reverse phase chromatography. The venom (1.3 g) was dissolved in 4 ml of 50 mM Tris-HCl (pH 7.5), and the insoluble material was removed by centrifugation (1,000×*g*) for 15 min at 4°C. The supernatant was applied on a Bio-Gel P-100 column (1.5×110 cm) equilibrated with 50 mM Tris-HCl buffer containing 0.1 M NaCl (pH 7.5), and the column was eluted with the same buffer at the flow rate of 5 ml/h. The fractions containing arginine esterase or fibrinogen clotting activity were pooled, dialyzed against 50 mM Tris-HCl, pH 7.5, overnight, and then concentrated with Diaflo UM 10 from Amicon (Beverly, USA). The active fractions were loaded on a Mono S cation-exchange chromatography column equilibrated with 50 mM Tris-HCl (pH 7.5). The bound enzyme was eluted with a linear salt gradient (0–0.6 M) in 50 mM Tris-HCl (pH 7.5) at the flow rate of 1.0 ml/min. The fractions containing arginine esterase activity were pooled, dialyzed against distilled water, and then concentrated by ultrafiltration. The enzyme was subsequently purified by Pro-RPC, with elution with a linear acetonitrile (0–100%) gradient for 60 min at 0.3 ml/min. The elution profile was monitored at 280 nm.

Enzyme Activity Assays—Arginine esterase activity was followed by the spectrophotometric procedure, with TAME as a substrate (8). In brief, a reaction mixture containing 1 ml of 1 mM substrate in 10 mM Tris-HCl (pH 7.5) was preincubated at 37°C for 10 min. The enzyme (10 μl) was added to the mixture and then the absorbance was monitored at 247 nm for 10 min. One unit of TAME activity was defined as the amount of enzyme catalyzing the hydrolysis of 1 μmol of TAME per min. The absorbance change accompanying the hydrolysis of 1 μmol of TAME per ml was 0.409 cm⁻¹·mM⁻¹ (8). The other substrates used for esterase activity measurement were BAEE, TLEE, and BAA, with measurement at 256 nm. One unit of arginine esterase activity was defined as the amount of enzyme necessary to hydrolyze 1.0 μmol of substrate per min.

Amidolytic activity was assayed at 25°C in 10 mM Tris-HCl, pH 7.4, by monitoring the hydrolysis of chromogenic substrates containing *p*-nitroanilide groups next to an arginine residue (V-L-K-NA, D-Val-Leu-Lys *p*-nitroanilide; Tos-G-P-R-NA, *N*α-*p*-tosyl-Gly-Pro-Arg *p*-nitroanilide; Bz-F-V-R-NA, *N*-benzoyl-Phe-Val-Arg *p*-nitroanilide; and Bz-P-F-R-NA, *N*α-benzoyl-Pro-Phe-Arg *p*-nitroanilide). The enzyme, which had been preincubated with the buffer for 3 min, was added to each substrate and then the absorbance change was measured at 405 nm. One unit of amidolytic activity was defined as the amount of enzyme necessary to hydrolyze 1.0 μmol of substrate per min.

Assaying of Clotting Activity—The fibrinogen clotting time was measured as described by Hofmann *et al.* (9). Briefly, the clotting time of 0.5 ml of bovine fibrinogen (0.7%) in 10 mM Tris-HCl buffer (pH 7.5) was measured

after the addition of 2 μg of enzyme. The time to the first appearance of fibrin strands was measured, with magnetic stirring at 37°C. A standard curve was obtained by varying amounts of NIH standard thrombin. Fibrinogen clotting activity was expressed in NIH equivalent units of thrombin.

Fibrinogenolytic Activity—Fibrinogenolytic activity was examined using a 1% bovine fibrinogen solution in saline. The enzyme (10 μg) was added to the solution, followed by incubation at 37°C. Aliquots of the reaction mixture were withdrawn at various time intervals and denatured by boiling for 5 min, and then the clots that formed were removed by centrifugation at 8,000×*g* for 10 min. The supernatant containing fibrinopeptides was analyzed by HPLC. The solution (100 μl) was loaded on a C₁₈ column (0.4×22 cm; Applied Biosystems, USA), and then analyzed essentially as described by Shimokawa and Takahashi (10). Linear gradient elution (0–30%) between solvent A (0.025 M ammonium acetate, pH 6.0) and solvent B (50% acetonitrile in 0.05 M ammonium acetate, pH 6.0) was performed for 40 min at the flow rate of 1 ml/min, the absorbance at 214 nm being monitored.

Fibrinolytic Activity—Fibrinolytic activity was evaluated by applying 2 μl of a test sample on a plate of fibrin produced by thrombin-mediated polymerization, with further incubation for 17 h at 37°C (11). The activity was determined from the area of lysis on the plate.

PAGE and Isoelectric Focusing on Polyacrylamide Gels—SDS-PAGE was performed according to Laemmli (12) using 10% polyacrylamide gels. The protein standards used were α-lactalbumin (14,200), soybean trypsin inhibitor (20,100), trypsinogen (24,000), carbonic anhydrase (29,000), glyceraldehyde-3-phosphate dehydrogenase (36,000), ovalbumin (45,000), and bovine serum albumin (66,000). Isoelectric focusing was performed with a Bio-Rad Model 111 Mini Isoelectric Focusing Cell (Richmond, USA) according to the manufacturer's procedure. Proteins were stained with Coomassie Brilliant Blue R-250 or a silver stain kit from Bio-Rad.

Amino Acid Composition—Amino acid composition analysis was carried out by HPLC involving precolumn derivatization of amino acids with phenylisothiocyanate (PITC), followed by reverse phase chromatography (13) for the quantitative determination of amino acids, using a Pierce amino acid standard solution (Rockford, USA).

Amino Acid Sequence—The partial amino acid sequence of the purified enzyme was determined by automatic sequencing with a Milligen 6600B amino acid sequencer, and performed at the Korea Basic Science Center in Seoul.

Proteolytic Activity Assay—Proteolytic activity was measured with azocasein according to a previously described method (6, 14).

Effects of Divalent Metal Cations and Inhibitors—The enzyme was preincubated with 5 mM of divalent metal cations (Ba²⁺, Cu²⁺, Mg²⁺, Mn²⁺, and Zn²⁺) and inhibitors (10 mM benzamidine, 5 mM EDTA, 5 mM EGTA, 5 mM cysteine, 2 mM PMSF, 10 mM β-mercaptoethanol, 50 μM soybean trypsin inhibitor, 1 mM aprotinin, and 10 U hirudin) at 37°C for 2 h. Then the substrate (Tos-G-P-R-NA) was added and the reaction mixture was incubated at 37°C for 2 min. The reaction was stopped by adding 100 μl of 50% acetic acid and then the absorbance was read at 405 nm.

Effect of pH—The enzyme (2 μ g) was dissolved in acetate buffer (50 mM, pH 3–6), Tris-HCl buffer (50 mM, pH 7–9), or phosphate buffer (50 mM, pH 10–11), and then incubated at room temperature for 2 h. The effect of pH on proteolytic activity was determined using a chromogenic substrate, Tos-G-P-R-NA, as described above.

Effect of Temperature—The enzyme (2 μ g) in 50 mM Tris-HCl buffer (pH 7.5) was incubated for 15 min at 10, 20, 30, 40, 50, 60, 70, and 80°C. The reaction mixtures were then cooled on ice and the effect of temperature on proteolytic activity was determined using a chromogenic substrate, Tos-G-P-R-NA, as described above.

Effect on Platelet Aggregation—This was essentially followed by the method of Willis and Tu (15). In brief, rat blood was mixed with 3.8% sodium citrate (9 : 1 v/v) in a plastic tube. Platelet-rich plasma (PRP) was collected after centrifuging the citrated blood at 200 \times g for 10 min. Platelet-poor plasma was obtained by centrifuging the blood at 500 \times g for 15 min. The platelet count was adjusted to 400–450 \times 10⁶/ml by adding PRP and PPP. The effect of calobin was studied according to a turbidimetric method by monitoring the change in light transmission using an aggregometer from Chrono-Log (Havertown, USA). PRP (450 μ l) was preincubated with 1 μ g of enzyme and 25 μ l of 10 mM CaCl₂ at 37°C for 2.5 min. The activator (5 μ l of 10 μ M ADP) was then added, and platelet aggregation was recorded over 5 min. The maximum aggregation response obtained on the addition of ADP in the absence of the enzyme was taken as 100%.

Protein Concentration Determination—Protein concentrations were determined by reading the absorbance at 280 nm or by the method of Bradford (16) using bovine serum albumin as a standard.

Construction of a cDNA Library—Total RNA was extracted from the venom glands of one freshly sacrificed adult snake, *A. caliginosus*, by the phenol procedure (17). The poly(A)⁺ fraction was purified by oligo (dT)-cellulose chromatography from US Biochemicals (Cleveland, USA). A cDNA library was constructed in λ ZAP II from venom gland poly(A)⁺ RNA using a cDNA kit from Stratagene (La Jolla, USA) according to the manufacturer's instructions, using standard procedures (18). Double-stranded cDNA was synthesized from 5 μ g of poly(A)⁺ RNA template, ligated to *Eco*RI-*Xho*I digested λ ZAP II DNA, and then packaged. The packaged library was plated on *Escherichia coli* XL1-Blue MRF' and amplified as a plate lysate on agar plates (18). It contained over 10⁶ independent phages (96% recombinant).

Design of Oligonucleotide Probes and Screening—A 20-meric oligonucleotide probe (5'-GTC/A ATT GGA GGT GAT GAA TG-3') was deduced and synthesized according to the N-terminal sequence of calobin and the nucleotide sequence of batroxobin (19, 20). The probe was ³²P-end-labeled with T4 polynucleotide kinase and [γ -³²P]ATP (21). The membrane replicas were pre-hybridized at 52°C for 3 h in pre-hybridization buffer [0.9 M sodium chloride, 0.09 M sodium citrate (pH 7.0), 0.2% (w/v) polyvinylpyrrolidone, 0.2% (w/v) Ficoll, 0.2% (w/v) BSA, 0.5% SDS, and 100 μ g/ml sheared, denatured salmon sperm DNA]. The membrane replicas were then hybridized at 52°C for 15 h in 30 ml of hybridization buffer [0.9 M sodium chloride, 0.09 M sodium citrate (pH 7.0), 0.2% (w/v) polyvinylpyrrolidone, 0.2% (w/v) Ficoll, 0.2% (w/v) BSA, 0.5% SDS, 10

mM EDTA, and 100 μ g/ml sheared, denatured salmon sperm DNA] containing 10 pmol of labeled oligonucleotide probe. Subsequent washes of the hybridized membrane filters were carried out in 6 \times SSC (1 \times SSC=0.15 M NaCl/0.015 M sodium citrate) and 0.1% (w/v) SDS as follows: three times at 25°C for 5 min each and once 50°C for 2 min. The filters were then exposed to X-ray films at -70°C using intensifying screens. The positive plaques were detected by autoradiography and further purified by isolating single plaques.

Sequencing of cDNA Clones—Phage inserts were excised from the λ ZAP II vector and recircularized in the presence of the ExAssist interference-resistant helper phage to form the pBlueScript SK-phagemid according to the manufacturer's instructions. DNA sequencing was performed by the dideoxy chain-termination method (22) on excised insert DNA, and cloned DNA digested with appropriate restriction enzymes and subcloned into M13 mp18/19.

RESULTS

Purification—The thrombin-like enzyme was isolated by a combination of gel filtration, Mono S ion exchange, and Pro-RPC chromatographies (Fig. 1s), and it was named calobin. Most fibrinogen clotting activity as well as arginine esterase activity was seen in the arrow region. The homogeneity of the final fraction is shown in Fig. 2s. Table I shows that the specific activity of the purified calobin, which was obtained in a purification yield of 2.1%, was 226 U/mg. The purification was 25-fold compared to that of the crude venom of *A. caliginosus*.

Chemical Properties—The molecular weight was estimated to be 34,000 by SDS-PAGE under reducing conditions (Fig. 2sA). The isoelectric point of calobin, as determined by isoelectric focusing, was 6.2 (Fig. 2sB). Treatment of calobin with endoglycosidase F changed the electrophoretic mobility of the protein, suggesting that it is a glycoprotein containing Asn-linked oligosaccharides (data not shown). The optimum pH for the enzyme activity was 8.0 when examined with Tos-G-P-R-NA as the substrate. The enzyme was stable in the range of pH 6 to 10. Its proteolytic activity decreased outside the range of pH 4 to 10. Its optimum temperature was 40°C and it was stable at 10 to 50°C, but the activity drastically decreased at above 60°C. The substrate specificity of calobin was investigated using various kinds of substrates (Table I). The enzyme hydrolyzed arginine esters, such as TAME and BAEE, but did not cleave TLEE or BAA. Calobin did not show any caseinolytic activity.

TABLE I. Arginine esterase activity and chromogenic substrate assay.

Substrate	Δ Absorbance/ min/mg	Activity (units/mg)
TAME	130.0	318
BAEE	115.0	281
TLEE	6.6	16
BAA	ng ^a	
D-Val-Leu-Lys-NA (plasmin)		211
N-p-Tosyl-Gly-Pro-Arg-NA (thrombin)		9,884
N-Benzoyl-Phe-Val-Arg-NA (trypsin)		6,650
N-Benzoyl-Pro-Phe-Arg-NA (kallikrein)		244

^ang means negligible.

Aprotinin, benzamidine, and soybean trypsin inhibitor showed partial inhibition, but PMSF had a significant inhibitory effect on the enzyme activity, suggesting that calobin is a serine-type protease (Table II). Hirudin, a specific thrombin inhibitor from *Hirudino medicinalis*, did not show an inhibitory action on calobin. A chelating agent, EDTA, did not affect the hydrolysis of Tos-G-P-R-NA, indicating calobin is not a metalloenzyme (Table II). The activity of calobin was enhanced by Mg²⁺, Mn²⁺, and Ba²⁺, but inhibited by Zn²⁺ and Cu²⁺ (Table III).

The amino acid composition of calobin after HCl hydrolysis is shown in Table II. Asx and Glx are abundant, but there are very few tyrosine and methionine residues.

Sequence Homology—The N-terminal amino acid sequence of calobin was compared with those of several serine proteases. Calobin showed high homology to other thrombin-like enzymes including ancrod and batroxobin with some deletions and insertions, and moderate homology to human α -thrombin and human kallikrein (Fig. 1). The N-terminal amino acid was found to be valine, as it is in most other thrombin-like enzymes.

Thrombin-Like Activity—Thrombin-like enzyme activity was found by three independent methods. First, when chromogenic substrates were treated with calobin, Tos-G-P-R-NA and Bz-F-V-R-NA, which are specific for thrombin, were easily hydrolyzed (Table I). Second, a fibrin clot was clearly visualized on mixing calobin with fibrinogen.

TABLE II Effects of various inhibitors on the activity of calobin. Calobin (2 μ g) was preincubated at 37°C with 0.1 ml of an inhibitor for 2 h. Then, enzyme activity was determined using a chromogenic substrate for thrombin, as described under "MATERIALS AND METHODS." These values represent % of the control and the means of triplicate experiments.

Inhibitors	Concentration	Relative activity (%)
None		100
Benzamidine	5 mM	75
EDTA	5 mM	103
EGTA	5 mM	83
Cysteine	5 mM	93
PMSF	2 mM	5
β -Mercaptoethanol	10 mM	44
Soybean trypsin inhibitor	50 μ M	68
Aprotinin	50 μ M	102
	1 mM	94
Hirudin	0.5 U/ml	100
	10 U/ml	91

The clotting activity was equivalent to 226 NIH thrombin units. Third, the HPLC profile of incubation mixtures of fibrinogen with calobin or thrombin demonstrated the cleavage of three chains, A α , B β , and γ , fibrinopeptides A and/or B being released. The peaks with retention times of 23 min and 32 min were fibrinopeptides A and B, respectively (Fig. 2A). Under the conditions used, calobin only released fibrinopeptide A in 1 h (Fig. 2B), while thrombin released both. Calobin was an A α and B β type of enzyme hydrolyzing the A α chain of fibrinogen fast but the B β chain slowly. After 6 h incubation with calobin, fibrinopeptides A and B released were almost equivalent (data not shown). In the absence of calobin, fibrinogen cleavage was negligible.




Fig 2. HPLC analysis of fibrinopeptides released on incubation of fibrinogen for 60 min with thrombin (A) or calobin (B). The experimental conditions are given under "MATERIALS AND METHODS." As the incubation time for calobin and fibrinogen was increased, fibrinopeptide B appeared, and equivalent amounts of fibrinopeptides A and B were released

	1	10	20	30	Ref							
Calobin	VIGGDE	ECNINE	HRFLV	ALY N	SR	SRTL	FCGG	present work				
Ancrod	VIGGDE	ECNINE	HRFLV	ALY D	ST	TN	NFL	CGG	28			
Batroxobin	VIGGDE	EC	D	IN	EP	PL	AFM	YSPRY	FCGM	19		
Crotalase	VIGGDE	ECNINE	HPFLV	ALY			DY	WX	QXFL	45		
Flavoxobin	VIGGDE	EC	D	IN	HPFLV	ALY	DA	W	SGRFL	CGG	27	
Okinaxobin I	VIGGDE	ECNINE	HRFLA	ALY	D					38		
CP-1	V	VGGDE	X	VINE	NS	S	IV	V	FX	SSGLI	XGGTL	40
CP-2	VIGGDE	X	VINE	HRFL	AL	VFX	SS	GF	L	XGGTL		40
Thrombin	I	VE	QDAE	VGLSP	WQ	MM	FR	KSP	QEE	L	LCGA	25
Trypsin	I	V	GGY	TG	ANT	VPY	Q	SLN		SGYH	FCGG	27

X means unknown.

Fig. 1 Comparison of the amino terminal sequences of calobin and other serine proteases.


```

1          20          40          60
GGCACGAGCTGCCGCTGCCGATTGTTGGCCACCCAGCTGCTTAATTTGACCAAGTAAAGT
      80          100
GCTGCTTGATCAAGAAGTCTCTGCTTGGGTTATCTGATTAGATTGATACAGTATCTC
120          140          160
AAGTTTAAAGTAAGGGACTGGGATCTTACAGGCCAAACAGTTTGTTCACGCAGAGTTGAA
180          200          220
GCTATGGTGTGATCAGCGTGCTAGCAAAACCTTCTGATACTACAGCTTTCTTACGCA
Met Val Leu Ile Ser Val Leu Ala Asn Leu Leu Ile Leu Gln Leu Ser Tyr Ala
240          260          280
CAAAAATCTTCTGAACTGGTCATTGGAGGTGATGAATGTAACATAAATGAACATCGT
Gln Lys Ser Ser Glu Leu Val Ile Gly Gly Asp Glu Cys Asn Ile Asn Glu His Arg
300          320          340
TTCCTTGTAGCCTTGTATAACTCTAGGTCTAGGACTTTGTTCTGCGGTGGGACTTTG
Phe Leu Val Ala Leu Tyr Asn Ser Arg Ser Arg Thr Leu Phe Cys Gly Gly Thr Leu
360          380          400
ATCAACCAGGAATGGTCTCACTGCTGCACACTGTGAAAGGAAAAATTTCCGGATA
Ile Asn Gln Glu Trp Val Leu Thr Ala Ala His Cys Glu Arg Lys Asn Phe Arg Ile
420          440
AAGCTTGGTATTCATAGCAAAAAGGTACCAAATGAGGATGAGCAGACAAGAGTCCCA
Lys Leu Gly Ile His Ser Lys Lys Val Pro Asn Glu Asp Glu Gln Thr Arg Val Pro
460          480          500
AAGGAGAAAGTCTTTTGTCTTAGTAGCAAAAACCTATACCCTTTGGGACAAGGACATC
Lys Glu Lys Phe Phe Cys Leu Ser Ser Lys Asn Tyr Thr Leu Trp Asp Lys Asp Ile
520          540          560
ATGTTGATCAGGCTGGACAGTCCTGTTAGCAACAGTGAACACATCGCACCTCTCAGCTTG
Met Leu Ile Arg Leu Asp Ser Pro Val Ser Asn Ser Glu His Ile Ala Pro Leu Ser Leu
580          600          620
CCTTCCAGCCCTCCCAGTGTGGGGTCAGTTTGCCGTATTATGGGATGGGGCAGAATCTCA
Pro Ser Ser Pro Pro Ser Val Gly Ser Val Cys Arg Ile Met Gly Trp Gly Arg Ile Ser
640          660          680
CCTACTAAAGAGACTTATCCCAGATGTCCCTCATTGTGCTAACATTAACCTACTCGAA
Pro Thr Lys Glu Thr Tyr Pro Asp Val Pro His Cys Ala Asn Ile Asn Leu Leu Glu
700          720          740
TATGAGATGTGTCGAGCACCTTACCCAGAATTTGGGTTGCCAGCGACAAGCAGAACA
Tyr Glu Met Cys Arg Ala Pro Tyr Pro Glu Phe Gly Leu Pro Ala Thr Ser Arg Thr
760          780          800
TTGTGTGCAGGTATCCTGGAAGGAGGGAAAAGATACATGTCTGGGGTGACTCTGGGGGA
Leu Cys Ala Gly Ile Leu Glu Gly Gly Lys Asp Thr Cys Arg Gly Asp Ser Gly Gly
820          840          860
CCCCTCATCTGTAAATGGACAATTCAGGGCATTGCATCTTGGGGAGACGATCCCTGTGTC
Pro Leu Ile Cys Asn Gly Gln Phe Gln Gly Ile Ala Ser Trp Gly Asp Asp Pro Cys Ala
880          900          920
CAACCGCATAAGCCTGCCGCTACACCAAGGTCTTCGATCATCTTGACTGGATCCAG
Pro His Lys Pro Ala Ala Tyr Thr Lys Val Phe Asp His Leu Asp Trp Ile Gln Gln
940          960          980
AGCATTATTGCAGGAATACAGATGCGTCTGCCCCCTGAAAACTTTTGAAAAAAG
Ser Ile Ile Ala Gly Asn Thr Asp Ala Ser Cys Pro Pro
1000
TTACGAGGAGAAAGTGAACATATTAGTACATCTATTCTATATCCCTAACCATATCC
1040          1060          1080
AACTACATTGGAATATATTCCCAGGCAGTAAACGTTTTTTAGACTCAAATAGGACTG
1100          1120          1140
CCTTCCGAGTAAGAAGTGTCTCAAAATAGTGTCTGCAGGGATCATGTCCCATTTAATTT
1160          1180          1200
CAGTATAAAACAATCTCAGTTAAATGGAGGCCTGTTTTAGGATGAGGTGCAAAAATTT
1220          1240          1260
TCTGACTCTAAAATGGACCATTCCAATATTTTAACTCTGAATATCTTTCCATTCT
1280          1300          1320
CTGTCCACTTCTGGGACAGTGGGGTCTTAATGCTCTTTGACGTTGTCTTCTTGCAG
1340          1360          1380
ACGTTTCATTACCCAGCTAGGTAACATCATCAGTGCTAGAAATATTCTCTTCTATTGG
1400          1420
TACTTCTGTGGCATTTACAATACGCTCATATGGAGTCATGCAGTCACCCCAACAACA
1440          1460          1480
TATCCATATACCCAGGTCCCATTTGCTTAAAGGATCCAGATTAACCCCACTT
1500          1520          1540
CCCAATCACTAAATAGAATCTTTTGAGAAATCGTGTTTTTCATGTAATTTCTCAGGTAT
1560          1580          1598
CCACCCATAAATCATATAAATCATTAAAAA

```

Fig. 4. The cDNA sequence of calobin and the predicted amino acid sequence of the precursor protein. The start ATG codon in the open reading frame and the stop TGA codon are boxed. The putative glycosylation site (Asn-Tyr-Thr) and the polyadenylation sequence (AATAAA) are also boxed. The amino acid residues that were confirmed on amino acid sequence analysis of calobin are underlined.

specific activity of calobin was higher. In fact, a second thrombin-like enzyme, which is thought to be enzyme B, was observed in the first gel-filtration step. Calobin did not exhibit microheterogeneity on isoelectric focusing.

Calobin has 238 amino acid residues with a molecular weight of 30,527, based on the DNA sequence from molecular cloning. This is pretty close to the result of

SDS-PAGE after deglycosylation with endoglycosidase F (data not shown). PMSF caused a rapid loss of amidolytic activity of calobin, and treatment with EDTA, EGTA, and cysteine did not affect the enzyme activity, indicating that calobin is a serine protease not a metalloprotease found in snake venom. The fibrinogen clotting activity of calobin, as well as that of batroxobin and okinaxobin, was unaffected

by hirudin. Thus, it is speculated that the region of the amino acid sequence of α -thrombin interacting with hirudin is different that of calobin. Calobin was found to act on the A α chain of fibrinogen fast, but the B β chain slowly. Most of thrombin-like enzymes from snake venoms, including ancrod (29) and batroxobin (30), act on fibrinogen to release fibrinopeptide A preferentially, while the enzymes from *Trimeresurus mucosquamatus* (37) and okinaxobin I (*Trimeresurus okinavensis*) readily split off fibrinopeptide B (38). Calobin hydrolyzed the ester bonds in TAME and BAEE as well as the amide bonds in Tos-G-P-R-NA and Bz-F-V-R-NA, which are specific substrates for thrombin. Arginine esterase activity was observed for β -fibrinogenases from other snake venoms as well (39).

On alignment of the N-terminal amino acid sequences of calobin, ancrod, batroxobin, crotalase, okinaxobin, and flavoxobin, they were found to be highly homologous to one another, although okinaxobin is a β -fibrinogenase. Interestingly, capillary permeability-increasing (CPI)-enzyme-1 and CPI-enzyme-2 from *A. caliginosus* showed remarkable similarities in their amino acid sequences to calobin. These are the same type of arginine esterase, but do not show thrombin-like activity (40). When endoglycosidase F was incubated with calobin, clotting activity decreased to 70% of the enzyme activity. This suggests that the carbohydrate moiety may play a role in stabilizing calobin (41). Several snake venoms were reported to contain platelet anti-aggregation peptides (42, 43), but the effects of crude venom from *A. caliginosus* and calobin on platelets were negligible at two concentrations of crude venom and calobin.

The predicted amino-terminal residue of calobin, valine, is preceded by 24 amino acids of prepeptides (signal peptides) and propeptides (zymogen peptides). Other serine proteases (trypsin and kallikrein) are each synthesized as a pre-zymogen before maturation (23, 24). A common feature of the signal peptides is a central core region rich in hydrophobic amino acid residues with large side chains and terminating in an apolar residue having a small side chain (alanine, glycine, and serine) (44). Therefore, we could predict that a possible site for cleavage of the prepeptide in the precursor is present after the Ala residue at position -7. The zymogen peptide is characterized by containing a region that is rich in a hydrophilic peptide. The hydrophilic peptide (amino acids -6 to -1) is probably a zymogen peptide. Based on the homology with other mature serine proteases, we could deduce the catalytic amino acid residues to be His⁴³, Asp⁸⁸, and Ser¹⁸⁴. The sequences around them are more highly conserved. This deduction is verified by the fact that calobin is strongly inhibited by PMSF. Calobin contains 12 cysteine residues. On alignment of the amino acid sequences of other thrombin-like enzymes (ancrod, batroxobin, and flavoxobin) (19, 27, 28), it may be presumed that the 12 cysteine residues in the sequence are all involved in the formation of six disulfide bridges (Cys⁷-Cys¹⁴¹, Cys²⁸-Cys⁴⁴, Cys⁷⁶-Cys²³⁵, Cys¹²⁰-Cys¹⁹⁰, Cys¹⁵²-Cys¹⁶⁹, and Cys¹⁸⁰-Cys²⁰⁵).

REFERENCES

1. Stocker, K.F. (1990) Snake venom proteins affecting hemostasis and fibrinolysis in *Medical Use of Snake Venom Proteins* (Stocker, K.F., ed.) pp. 97-160, CRC Press, Boca Raton
2. Bjarnason, J.B. and Fox, J.W. (1994) Hemorrhagic metalloproteinases from snake venom. *Pharmacol. Ther.* **62**, 325-372
3. Theodor, I. and Pirkle, H. (1991) Thrombin-like enzymes from snake venoms in *Handbook of Natural Toxins* (Tu, A.T., ed.) Vol. 5, pp. 225-252, Marcel Dekker, New York
4. Haimov, M. and Danese, C. (1973) Prevention of acute experimental arterial thrombosis by defibrination. *Vasc. Surg.* **7**, 206-212
5. Furukawa, K. and Ishimaru, S. (1990) Use of thrombin-like snake venom enzymes in the treatment of vascular occlusive diseases in *Medical Use of Snake Venom Proteins* (Stocker, K.F., ed.) pp. 161-173, CRC Press, Boca Raton
6. Hahn, B.S., Chang, I.M., and Kim, Y.S. (1995) Purification and characterization of piscivorases I and II, the fibrinolytic enzymes from eastern cottonmouth moccasin venom (*Agkistrodon piscivorus piscivorus*). *Toxicon* **33**, 929-941
7. Suzuki, T. and Takahashi, H. (1984) Purification of two thrombin-like enzymes from the venom of *Agkistrodon caliginosus* (Kankoku-mamushi). *Toxicon* **22**, 29-38
8. Walsh, K.A. and Wilcox, P.E. (1970) Serine protease in *Methods in Enzymology* (Permann, G.E., ed.) Vol. 19, pp. 31-41, Academic Press, New York
9. Hofmann, H., Dumarey, C., and Bon, C. (1983) Blood coagulation induced by *Bothrops atrox* venom: Identification and properties of a factor X activator. *Biochimie* **65**, 201-210
10. Shimokawa, K.I. and Takahashi, H. (1995) Comparative study of fibrinogen degradation by four arginine ester hydrolases from the venom of *Agkistrodon caliginosus* (Kankoku-mamushi). *Toxicon* **33**, 179-186
11. Astrup, T. and Mulertz, S. (1952) The fibrin plate method for the estimation of fibrinolytic activity. *Arch. Biochem. Biophys.* **40**, 346-351
12. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685
13. Williams, K.R., Neice, R.L., Aterton, D., Fowler, A.V., Kutny, K., and Smith, A.J. (1988) The size, operation, and technical capabilities of protein and nucleic acid core facilities. *FASEB. J.* **2**, 3124-3130
14. Beynon, R.J. and Kay, J. (1978) The inactivation of native enzymes by a neutral proteinase from rat intestinal muscle. *Biochem. J.* **173**, 291-298
15. Willis, T.W. and Tu, A.T. (1988) Purification and biochemical characterization of atroxase, a nonhemorrhagic fibrinolytic protease from western diamondback rattle snake venom. *Biochemistry* **27**, 4769-4777
16. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**, 248-254
17. Chomczynski, P. and Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* **162**, 156-159
18. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
19. Itoh, N., Tanaka, N., Mihashi, S., and Yamashina, I. (1987) Molecular cloning and sequence analysis of cDNA for batroxobin, a thrombin-like snake venom enzyme. *J. Biol. Chem.* **262**, 3132-3135
20. Itoh, N., Tanaka, N., Funakoshi, I., Kawasaki, T., Mihashi, S., and Yamashina, I. (1988) Organization of the gene for batroxobin, a thrombin-like snake venom enzyme. *J. Biol. Chem.* **263**, 7628-7631
21. Berkner, K.L. and Folk, W.R. (1977) Polynucleotide kinase exchange reaction. *J. Biol. Chem.* **252**, 3176-3184
22. Sanger, F., Nicklen, S., and Coulson, A.R. (1977) DNA sequencing with chain-termination inhibitors. *Proc. Natl. Acad. Sci. USA* **74**, 5463-5467
23. Macdonald, R.J., Stary, S.J., and Swift, G.H. (1982) Two similar but nonallelic rat pancreatic trypsinogens. *J. Biol. Chem.* **257**, 9724-9732
24. Chung, D.W., Fujikawa, K., McMullen, B.A., and Davie, E.W. (1986) Human plasma prekallikrein, a zymogen to a serine

- protease that contains four tandem repeats. *Biochemistry* **25**, 2410-2417
25. Butkowski, R.J., Elion, J., Downing, M.R., and Mann, K.G. (1977) Primary structure of human prothrombin 2 and α -thrombin. *J. Biol. Chem.* **252**, 4942-4957
 26. Magnusson, S., Peterson, T.W., Sottrup-Jensen, L., and Claeys, H. (1975) Complete primary structure of prothrombin: Isolation, structures and reactivity of ten carboxylated glutamic acid residues, and regulation of prothrombin activation by thrombin in *Proteases and Biological Control* (Reich, E., Rifkin, D.B., and Shaw, E., eds.) pp. 123-149, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
 27. Shieh, T.-C., Kawabata, S.-I., Kihara, H., Ohno, M., and Iwanaga, S. (1988) Amino acid sequence of a coagulation enzyme, flavoxobin, from *Trimeresurus flavoviridis* venom. *J. Biochem.* **103**, 596-605
 28. Au, L.C., Lin, S.B., Chou, J.S., Teh, G.W., Chang, K.J., and Shih, C.M. (1993) Molecular cloning and sequence analysis of cDNA for anecrod, a thrombin-like enzyme from the venom of *Calloselasma rhodostoma*. *Biochem. J.* **294**, 387-390
 29. Nolan, C., Hall, L.S., and Barlow, G.H. (1976) Anecrod, the coagulating enzyme from Malayan Pit Viper (*Agkistrodon rhodostoma*) venom in *Methods in Enzymology* (Lorand, L., ed.) Vol. 45, pp. 205-213, Academic Press, New York
 30. Aragon, F. and Gubensek, F. (1981) *Bothrops asper* venom from the Atlantic and Pacific zones of Costa Rica. *Toxicon* **19**, 797-805
 31. Stocker, K. (1978) *Handbook of Experimental Pharmacology* (Markwardt, F., ed.) Vol. 46, pp. 451-484, Springer, Berlin
 32. Pirkle, H., Theodor, I., Miyada, D., and Simmons, G. (1986) Thrombin-like enzyme from the venom of *Bitis gabonica*. Purification, properties and coagulant actions. *J. Biol. Chem.* **261**, 8830-8835
 33. Markland, F.S. and Damus, P.S. (1971) Purification and properties of a thrombin-like enzyme from the venom of *Crotalus asamanteus* (eastern diamondback rattlesnake). *J. Biol. Chem.* **246**, 6460-6473
 34. Shu, Y.Y., Moran, J.B., and Geren, C.R. (1983) A thrombin-like enzyme from timber rattlesnake venom. *Biochem. Biophys. Acta* **748**, 236-244
 35. Shieh, T.-C., Tanaka, S., Kihara, H., Ohno, M., and Makisumi, S. (1985) Purification and characterization of a coagulant enzyme from *Trimeresurus flavoviridis* venom. *J. Biochem.* **98**, 713-721
 36. Latalo, Z.S. (1983) Retrospective study on complications and adverse effects of treatment with thrombin-like enzymes, a multicenter trial. *Thromb. Haemostas.* (Stuttgart) **50**, 604-609
 37. Hung, C.C., Huang, K.F., and Chiou, S.H. (1994) Characterization of one noble venom protease with β -fibrinogenase activity from the Taiwan habu (*Trimeresurus mucrosquamatus*). *Biochem. Biophys. Res. Commun.* **205**, 1707-1715
 38. Iwasaki, A., Shieh, T.C., Shimohigashi, Y., Waki, M., Kihara, H., and Ohno, M. (1990) Purification and characterization of a coagulation enzyme, okinaxobin I, from the venom of *Trimeresurus okinavensis* (himehabu snake) which releases fibrinopeptide B. *J. Biochem.* **108**, 822-828
 39. Nikai, T., Katano, E., Komori, Y., and Sugihara, H. (1988) β -Fibrinogenase from the venom of *Agkistrodon p. piscivorus*. *Comp. Biochem. Physiol.* **89B**, 509-515
 40. Shimokawa, K.I. and Takahashi, H. (1993) Some properties of a capillary permeability-increasing enzyme-2 from the venom of *Agkistrodon caliginosus* (Kankoku-Mamushi). *Toxicon* **31**, 1221-1227
 41. Takeuchi, M., Takasaki, S., and Kobata, A. (1989) Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. *Proc. Natl. Acad. Sci. USA* **86**, 7819-7822
 42. Huang, T.F., Holt, J.C., Kirby, E.P., and Niewiarowski, S. (1987) Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on the glycoprotein IIb-IIIa complex. *J. Biol. Chem.* **262**, 16157-16163
 43. Gan, Z.R., Gould, R.J., Jacobs, J.W., Friedman, P.A., and Polokoff, M.A. (1988) A potent platelet aggregation inhibitor from the venom of the viper, *Echis carinatus*. *J. Biol. Chem.* **263**, 19827-19832
 44. Pugsley, A.P. (1989) *Protein Targeting*, pp. 45-111, Academic Press, San Diego
 45. Pirkle, H., Markland, F.S., Theodor, I., Baumgartner, R., Bajwa, S.S., and Kirkakossian, H. (1981) The primary structure of crotalase, a thrombin-like venom enzyme, exhibits close homology to kallikrein than to other serine protease. *Biochem. Biophys. Res. Commun.* **99**, 715

Supplemental Materials

TABLE Is. Specific activity and yield of calobin at each stage of purification.

Step	Total protein (mg)	Total activity	Specific activity (NIH units)
Crude venom	1,300.0	11,700.0	9.0
Bio-Gel P-100	113.5	7,943.6	70.0
Mono S	36.2	3,623.0	100.0
Pro-RPC	1.1	248.6	226.0

TABLE IIs. Amino acid content of calobin (residues/mol).

Amino acid	Calculated value ^c	Amino acid	Calculated value ^c
Asx ^a	35.1 (25)	Met	4.4 (3)
Thr	16.0 (12)	Ile	17.2 (17)
Ser	20.8 (19)	Leu	22.2 (19)
Glx ^a	24.2 (19)	Tyr	6.1 (6)
Pro	20.4 (19)	Phe	13.9 (8)
Gly	27.4 (19)	His	8.4 (7)
Ala	18.8 (14)	Lys	10.1 (12)
Val	18.1 (10)	Arg	17.4 (12)
Cya ^b	14.5 (12)	Trp	14.2 (5)
		Total	309.1 (238)

^aAsx and Glx mean the sums of asparagine and aspartic acid, and glutamine and glutamic acid, respectively. ^bCya means the sum of cysteic acid and oxidized cystine. ^cValues in parentheses are the numbers of amino acid residues predicted from the cDNA sequence.

TABLE IIIs. Effects of divalent metal cations on the activity of calobin. Calobin (2 μ g) dissolved in 50 mM Tris-HCl (pH 7.5) was preincubated with each divalent cation at 37°C for 2 h. Activity was determined using a chromogenic substrate for thrombin, as described under "MATERIALS AND METHODS." These values represent % of the control and the means of triplicate experiments.

Divalent cations	Concentration (mM)	Relative activity (%)
None		100
Mg ²⁺	5	118
Mn ²⁺	5	104
Zn ²⁺	5	21
Ba ²⁺	5	108
Cu ²⁺	5	5






Fig. 1s. Isolation of calobin from the venom of *A. caliginosus*. The procedure is described under "MATERIALS AND METHODS" (a) Chromatography on Bio-Gel P-100. The eluant was monitored by spectrophotometry at 280 nm (●) Arginine esterase activity (□) was measured and the active fractions were pooled (—). (b) Mono S chromatography, (c) Pro-RPC chromatography.




Fig. 2s Homogeneity of the purified calobin from a Pro-RPC column. Polyacrylamide gel electrophoresis and isoelectric focusing of calobin. The conditions are given under "MATERIALS AND METHODS." (A) SDS-PAGE under reducing conditions with SDS, (B) IEF on a 10% acrylamide gel containing 2% ampholyte (pH 3-10) Lane 1, pI markers; and lane 2, calobin




Fig. 3s. Partial restriction map of the longest clone sequenced. The open reading frame is shown in a stippled box